ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 001,80
-0,48%
Dow Jones
38 923,47
0,10%
DAX
18 557,27
-0,48%
Brent Oil
79,435
-0,56%
Bitcoin
69 031,99
-2,44%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. RVL Pharmaceuticals PLC (RVLP)

  7. RVL Pharmaceuticals PLC (RVLP) Actualités

RVLP

RVL Pharmaceuticals (RVLP)

RVL Pharmaceuticals PLC
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:RVLP
DateHeureSourceTitreSymboleSociété
17/01/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVLPRVL Pharmaceuticals PLC
27/11/202312h50GlobeNewswire Inc.RVL Completes Financial RestructuringNASDAQ:RVLPRVL Pharmaceuticals PLC
16/11/202315h11Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:RVLPRVL Pharmaceuticals PLC
01/11/202321h27Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:RVLPRVL Pharmaceuticals PLC
23/10/202322h23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVLPRVL Pharmaceuticals PLC
18/10/202322h00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RVLPRVL Pharmaceuticals PLC
12/10/202312h50GlobeNewswire Inc.RVL Pharmaceuticals plc Announces Prepackaged Reorganization of Certain U.S. SubsidiariesNASDAQ:RVLPRVL Pharmaceuticals PLC
05/09/202313h45Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:RVLPRVL Pharmaceuticals PLC
31/08/202320h23Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:RVLPRVL Pharmaceuticals PLC
30/08/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RVLPRVL Pharmaceuticals PLC
25/08/202323h21Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:RVLPRVL Pharmaceuticals PLC
23/08/202323h30Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:RVLPRVL Pharmaceuticals PLC
23/08/202322h05GlobeNewswire Inc.RVL Pharmaceuticals plc to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:RVLPRVL Pharmaceuticals PLC
17/08/202322h05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RVLPRVL Pharmaceuticals PLC
16/08/202314h00GlobeNewswire Inc.RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesNASDAQ:RVLPRVL Pharmaceuticals PLC
14/08/202315h15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RVLPRVL Pharmaceuticals PLC
14/08/202312h50GlobeNewswire Inc.RVL Pharmaceuticals plc Reports Second Quarter 2023 Financial Results; Provides Update on Strategic Business ReviewNASDAQ:RVLPRVL Pharmaceuticals PLC
02/08/202314h30GlobeNewswire Inc.RVL Pharmaceuticals plc to Discuss Second Quarter 2023 Financial Results and Provide Commercial UpdateNASDAQ:RVLPRVL Pharmaceuticals PLC
05/07/202312h50GlobeNewswire Inc.RVL Pharmaceuticals plc Provides Business UpdateNASDAQ:RVLPRVL Pharmaceuticals PLC
16/06/202322h02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RVLPRVL Pharmaceuticals PLC
15/06/202322h15GlobeNewswire Inc.RVL Pharmaceuticals plc Announces Result of Proposal to Approve a Waiver of Offer Obligations under Rule 9 of the Irish Takeover Rules at Annual General MeetingNASDAQ:RVLPRVL Pharmaceuticals PLC
11/05/202322h24Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:RVLPRVL Pharmaceuticals PLC
11/05/202312h50GlobeNewswire Inc.RVL Pharmaceuticals plc Reports First Quarter 2023 Financial Results; Provides Commercial UpdateNASDAQ:RVLPRVL Pharmaceuticals PLC
04/05/202312h50GlobeNewswire Inc.RVL Pharmaceuticals plc to Discuss First Quarter 2023 Financial Results and Provide Commercial UpdateNASDAQ:RVLPRVL Pharmaceuticals PLC
24/04/202322h26Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:RVLPRVL Pharmaceuticals PLC
24/04/202322h17Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:RVLPRVL Pharmaceuticals PLC
24/04/202322h13Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:RVLPRVL Pharmaceuticals PLC
03/04/202319h00GlobeNewswire Inc.RVL Pharmaceuticals Announces that Upneeq® Wins “Best Eye Drop for Drooping Lids” NewBeauty in 13th Annual Beauty AwardsNASDAQ:RVLPRVL Pharmaceuticals PLC
20/03/202311h50GlobeNewswire Inc.RVL Pharmaceuticals plc Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Commercial UpdateNASDAQ:RVLPRVL Pharmaceuticals PLC
15/03/202311h50GlobeNewswire Inc.RVL Pharmaceuticals plc to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Commercial UpdateNASDAQ:RVLPRVL Pharmaceuticals PLC
 Showing the most relevant articles for your search:NASDAQ:RVLP

Dernières Valeurs Consultées

EU
SGFD
Soc Gen 0.594%feb26
BIT
I06990
Intesa Sanpaolo
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés